Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Aphasia, Behaviour disorder, Computerised tomogram, Confusional state, Decreased interest
Clinical narrative: he was no longer behaving in the same fashion; would giggle inappropriately when asked questions; needed to be reminded to chew and swallow food, could no longer feed and dress himself, no longer recognized people in his life; no longer had an interest in the many things he previously was interested in; become incontinent; became confused easil, was confused by simple directions; speech loss, He had stopped talking; This spontaneous case was reported by a patient family member or friend and describes the occurrence of BEHAVIOUR DISORDER (he was no longer behaving in the same fashion), APHASIA (speech loss, He had stopped talking), CONFUSIONAL STATE (became confused easil, was confused by simple directions), MEMORY IMPAIRMENT (needed to be reminded to chew and swallow food, could no longer feed and dress himself, no longer recognized people in his life) and DECREASED INTEREST (no longer had an interest in the many things he previously was interested in) in a 43-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014C21A and 026A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Neurological impairment (Reaction--loss of speech, cognitive and physical impairment) since 1980, Seizures since 2019, Drug allergy (Haldol), Drug allergy (Accutane), Drug allergy (Inderol) and Drug allergy (Depakote). Concomitant products included CLONAZEPAM and ZIPRASIDONE for Myocardial infarction, LEVETIRACETAM (KEPRA) for Seizure.   On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-Apr-2021, the patient experienced APHASIA (speech loss, He had stopped talking). On 01-Jun-2021, the patient experienced CONFUSIONAL STATE (became confused easil, was confused by simple directions), DECREASED INTEREST (no longer had an interest in the many things he previously was interested in) and INCONTINENCE (become incontinent). On 23-Jun-2021, the patient experienced MEMORY IMPAIRMENT (needed to be reminded to chew and swallow food, could no longer feed and dress himself, no longer recognized people in his life). On an unknown date, the patient experienced BEHAVIOUR DISORDER (he was no longer behaving in the same fashion) and INAPPROPRIATE AFFECT (would giggle inappropriately when asked questions). At the time of the report, BEHAVIOUR DISORDER (he was no longer behaving in the same fashion) and INAPPROPRIATE AFFECT (would giggle inappropriately when asked questions) outcome was unknown and APHASIA (speech loss, He had stopped talking), CONFUSIONAL STATE (became confused easil, was confused by simple directions), MEMORY IMPAIRMENT (needed to be reminded to chew and swallow food, could no longer feed and dress himself, no longer recognized people in his life), DECREASED INTEREST (no longer had an interest in the many things he previously was interested in) and INCONTINENCE (become incontinent) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Jun-2021, Computerised tomogram: normal (normal) Normal. On 06-Jun-2021, Electroencephalogram: normal (normal) Normal. On 06-Jun-2021, Magnetic resonance imaging: normal (normal) Normal.         Treatment information in response to events was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 08-Sep-2021: Significant followup received contains event outcome and date, concomitant product and dosage details was updated.